Company: CERO
Filing Date: 2025-07-18
Form Type: 8-K
Source: 0001213900-25-065655
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-18
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01 Financial Statements and Exhibits.

(d)

  Exhibit      Description                                                                                                                                                                                           
  Number                                                                                                                                                                                                             
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  3.1†         Certificate of Designation of Preferences, Rights and Limitations of the Series D Convertible Preferred Stock, dated April 22, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Cu...  
  10.1†        Securities Purchase Agreement, dated of April 21, 2025, by and among CERo Therapeutics Holdings, Inc., and the investors signatory thereto (incorporated by reference to Exhibit 10.1 of the Comp...  
  10.2†        Form of Amendment to the Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K (File No. 001-40877) filed on June 30, 2025).           
  104          Cover Page Interactive Data File-the cover                                                                                                                                                            

  Certain                                                                                                                               
  Filed                                                                                                                                 

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                           CERO THERAPEUTICS HOLDINGS, INC.                               
  Date: July 18, 2025      By:                                   /s/ Chris Ehrlich        
                                                                 Chris Ehrlich            
                                                                 Chief Executive Officer